William P. Tew

15.0k citations

217 papers · 9.3k indexed · 7 hit papers · h-index 44

Impact in

Geriatrics and Gerontology top 0.05%
- Frailty in Older Adults
Reproductive Medicine top 0.2%
- Ovarian cancer diagnosis and treatment

Papers in

Reproductive Medicine 98
- Ovarian cancer diagnosis and treatment 98
Geriatrics and Gerontology 41
- Frailty in Older Adults 38

Co-authors: Arti Hurria Stuart M. Lichtman Supriya G. Mohile Heidi D. Klepin Vani Katheria Harvey Jay Cohen Ajeet Gajra Cary P. Gross
Journals: Journal of Clinical Oncology (57 papers)Gynecologic Oncology (50 papers)Journal of Geriatric Oncology (11 papers)Cancer (9 papers)International Journal of Gynecological Cancer (9 papers)
Partner nations: United States Canada Japan

In The Last Decade

William P. Tew

208 papers receiving 9.1k citations

Hit Papers

7 papers align trajectories log scale

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update 2025 · 15 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2025 Journal of Clinical Oncology
2020 CA A Cancer Journal for Clinicians
2018 Journal of Clinical Oncology
2016 Journal of Clinical Oncology
2016 Gynecologic Oncology
2016 Journal of Clinical Oncology
2011 Journal of Clinical Oncology

Peers

Countries citing papers authored by William P. Tew

Since Specialization

Citations

This map shows the geographic impact of William P. Tew's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William P. Tew with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William P. Tew more than expected).

Fields of papers citing papers by William P. Tew

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William P. Tew. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William P. Tew. The network helps show where William P. Tew may publish in the future.

Co-authors

The 25 scholars most cited alongside William P. Tew, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with William P. Tew Line = papers co-authored together William P. Tew links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody–drug conjugate Gynecologic Oncology ·Paul Johannet, Matthew Flint, M. Herman Chui, Jason Konner, Claire F. Friedman, Angela K. Green, Robin Guo, Martee L. Hensley, Chrisann Kyi, Ying Liu, Vicky Makker, Maria M. Rubinstein, Paul Sabbatini, William P. Tew, Michael B. Foote, Britta Weigelt, Carol Aghajanian, Rachel N. Grisham, Roisin E. O’Cearbhaill	2025	0
2	Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update Obstetrical & Gynecological Survey ·Stéphanie Gaillard, Christina Lacchetti, Deborah K. Armstrong, William A. Cliby, Mitchell I. Edelson, Agustin A. García, Rahel G. Ghebre, Gregory M. Gressel, Jamie Lesnock, Larissa A. Meyer, Kathleen N. Moore, Roisin E. O’Cearbhaill, Alexander Olawaiye, Ritu Salani, Dee Sparacio, Willemien J. van Driel, William P. Tew	2025	0
3	Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Clinical Insights JCO Oncology Practice ·William P. Tew, Christina Lacchetti, Stéphanie Gaillard	2025	1
4	A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer. Journal of Clinical Oncology ·Angela Green, Qin Zhou, Alexia Iasonos, William A. Zammarrelli, Britta Weigelt, Lora H. Ellenson, Rashmi Chhetri-Long, Pooja Shah, Vania Hom, Joseph P. Erinjeri, Iva Petkovska, Sarat Chandarlapaty, Seth Cohen, Rachel N. Grisham, Jason Konner, Maria M. Rubinstein, William P. Tew, Tiffany A. Troso-Sandoval, Carol Aghajanian, Vicky Makker	2024	4
5	Vascular resection and reconstruction in recurrent granulosa cell tumor Gynecologic Oncology Reports ·Lindsey Finch, Sharif H. Ellozy, Jaspreet S. Sandhu, Tulsi Patel, William P. Tew, S. Dennis	2024	1
6	LBA45 Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa) Annals of Oncology ·J.F. Liu, Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher, William P. Tew, Noelle Cloven, Carolyn Y. Muller, David Bender, Richard G. Moore, M. Menon, Steven Waggoner, Melissa A. Geller, Keiichi Fujiwara, Stacy D. D’Andre, Michael E. Carney, Angeles Alvarez Secord, Joan Walker, M.A. Bookman	2023	2
7	Falls prechemotherapy and toxicity‐related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trial Cancer ·Jingran Ji, Marie Bae, Can‐Lan Sun, Tanya M. Wildes, Rachel A. Freedman, Allison Magnuson, Tracey L. O’Connor, Beverly Moy, Heidi D. Klepin, Andrew E. Chapman, William P. Tew, Efrat Dotan, Mary Anne Fenton, Heeyoung Kim, Vani Katheria, Cary P. Gross, Harvey Jay Cohen, Hyman B. Muss, Mina S. Sedrak	2023	6
8	Risk Factors for Hospitalizations Among Older Adults with Gastrointestinal Cancers The Oncologist ·Daneng Li, Can‐Lan Sun, Rebecca Allen, Christiana Crook, Abrahm Levi, Richard Ballena, Heidi D. Klepin, Rawad Elias, Supriya G. Mohile, William P. Tew, Cynthia Owusu, Hyman B. Muss, Stuart M. Lichtman, Cary P. Gross, Andrew E. Chapman, Ajeet Gajra, Harvey Jay Cohen, Vani Katheria, Arti Hurria, William Dale	2022	3
9	Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update Journal of Clinical Oncology ·William P. Tew, Christina Lacchetti, Elise C. Kohn, (unknown)	2022	51
10	Safety and Efficacy of Arterially Directed Liver Therapies in the Treatment of Hepatic Metastatic Ovarian Cancer: A Retrospective Single-Institution Study Journal of Vascular and Interventional Radiology ·Eduardo A. Lacayo, Sara Velayati, Ahmed Elsakka, Lynn A. Brody, Joseph P. Erinjeri, Etay Ziv, F. Edward Boas, Constantinos T. Sofocleous, Mikhail Silk, Vicky Makker, William P. Tew, Hooman Yarmohammadi	2021	3
11	Older adult participation in cancer clinical trials: A systematic review of barriers and interventions CA A Cancer Journal for Clinicians ·Mina S. Sedrak, Rachel A. Freedman, Harvey Jay Cohen, Hyman B. Muss, Aminah Jatoi, Heidi D. Klepin, Tanya M. Wildes, Jennifer Le‐Rademacher, Gretchen Kimmick, William P. Tew, Kevin George, Simran Padam, Jennifer Liu, Andrew R. Wong, Andrea Lynch, Benjamin Djulbegović, Supriya G. Mohile, William Dale Hit paper breakdown →	2020	287
12	PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Obstetrical & Gynecological Survey ·William P. Tew, Christina Lacchetti, Annie Ellis, Kathleen Maxian, Susana Banerjee, Michael A. Bookman, Monica B. Jones, Jung‐Min Lee, Stéphanie Lheureux, Joyce F. Liu, Kathleen N. Moore, Carolyn Y. Muller, Patricia Rodríguez, Christine Walsh, Shannon N. Westin, Elise C. Kohn	2020	10
13	PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Journal of Clinical Oncology ·William P. Tew, Christina Lacchetti, Annie Ellis, Kathleen Maxian, Susana Banerjee, Michael A. Bookman, Monica B. Jones, Jung Min Lee, Stéphanie Lheureux, Joyce F. Liu, Kathleen N. Moore, Carolyn Y. Muller, Patricia Rodríguez, Christine Walsh, Shannon N. Westin, Elise C. Kohn	2020	191
14	Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery Journal of Gynecologic Oncology ·Ying L. Liu, Olga T. Filippova, Qin Zhou, Alexia Iasonos, S. Dennis, Oliver Zivanovic, Yukio Sonoda, Ginger J. Gardner, Vance Broach, Roisin E. O’Cearbhaill, Jason Konner, Carol Aghajanian, Kara Long Roche, William P. Tew	2019	23
15	Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer Journal of Clinical Oncology ·Arti Hurria, Supriya G. Mohile, Ajeet Gajra, Heidi D. Klepin, Hyman B. Muss, Andrew E. Chapman, Feng Tao, David Smith, Can-Lan Sun, Nienke A. de Glas, Harvey Jay Cohen, Vani Katheria, Caroline Doan, Laura Zavala, Abrahm Levi, Chie Akiba, William P. Tew Hit paper breakdown →	2016	402
16	Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline Obstetrical & Gynecological Survey ·Alexi A. Wright, Kari Bohlke, Deborah K. Armstrong, Michael A. Bookman, William A. Cliby, Robert L. Coleman, Don S. Dizon, Joseph J. Kash, Larissa A. Meyer, Kathleen N. Moore, Alexander Olawaiye, Jessica Oldham, Ritu Salani, Dee Sparacio, William P. Tew, Ignace Vergote, Mitchell I. Edelson	2016	19
17	Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study Journal of Clinical Oncology ·Arti Hurria, Kayo Togawa, Supriya G. Mohile, Cynthia Owusu, Heidi D. Klepin, Cary P. Gross, Stuart M. Lichtman, Ajeet Gajra, Ravi Bhatia, Vani Katheria, S. Klapper, Kurt Hansen, Rupal Ramani, Mark S. Lachs, F. Lennie Wong, William P. Tew Hit paper breakdown →	2011	1248
18	Phase II Study of Intraperitoneal Paclitaxel Plus Cisplatin and Intravenous Paclitaxel Plus Bevacizumab As Adjuvant Treatment of Optimal Stage II/III Epithelial Ovarian Cancer Journal of Clinical Oncology ·Jason Konner, Diana M. Grabon, Scott R. Gerst, Alexia Iasonos, Howard T. Thaler, S. Pezzulli, Paul Sabbatini, Katherine M. Bell‐McGuinn, William P. Tew, Martee L. Hensley, David R. Spriggs, Carol Aghajanian	2011	44
19	Distress in Older Patients With Cancer Journal of Clinical Oncology ·Arti Hurria, Daneng Li, Kurt Hansen, Sujata Patil, Ravi Gupta, Christian J. Nelson, Stuart M. Lichtman, William P. Tew, Paul A. Hamlin, Enid Zuckerman, Jonathan Gardes, Sewanti Limaye, Mark S. Lachs, Eva Kelly	2009	101
20	The effects of phospho citrate on experimentally induced nephro calcinosis Kidney International ·William P. Tew, C D Malis, W. Gordon Walker	1981	1

About William P. Tew

William P. Tew is a scholar working on Reproductive Medicine, Geriatrics and Gerontology, Obstetrics and Gynecology, Oncology and Pulmonary and Respiratory Medicine, having authored 217 papers that have together received 9.3k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (98 papers), Frailty in Older Adults (38 papers), Endometrial and Cervical Cancer Treatments (35 papers), Intraperitoneal and Appendiceal Malignancies (31 papers), PARP inhibition in cancer therapy (22 papers), Nutrition and Health in Aging (19 papers), Cancer survivorship and care (15 papers) and Renal cell carcinoma treatment (11 papers). The work is most often cited by research in Geriatrics and Gerontology (2.5k citations), Reproductive Medicine (1.9k citations), Obstetrics and Gynecology (990 citations), Oncology (3.3k citations) and Physiology (1.5k citations). William P. Tew has collaborated with scholars based in United States, Canada and Japan. Frequent co-authors include Arti Hurria, Stuart M. Lichtman, Supriya G. Mohile, Heidi D. Klepin, Vani Katheria, Harvey Jay Cohen, Ajeet Gajra, Cary P. Gross, Cynthia Owusu and William Dale. Their work appears in journals such as Journal of Clinical Oncology, Gynecologic Oncology, Journal of Geriatric Oncology, Cancer and International Journal of Gynecological Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact